#Industry News
LEICA BIOSYSTEMS RECEIVES FDA’S ENFORCEMENT DISCRETION FOR USE OF APERIO IMAGESCOPE DX VIEWING SOFTWARE FOR REMOTE DIAGNOSIS DURING COVID-19 EMERGENCY
REMOTE DIAGNOSIS DURING COVID-19 EMERGENCY
Published: 03 April 2020
VISTA, CA, April 3, 2020 – Leica Biosystems, the global leader in pathology workflow solutions, today announced it has received notification from the U.S. Food & Drug Administration (FDA) that its Aperio ImageScope DX Viewer with images acquired on the Aperio AT2 DX Scanner can be used for remote diagnosis under emergency use. This application will allow Pathologists to safely view and diagnose Pathology cases from remote locations in response to the COVID-19 pandemic.